Practice Test Geeks(CLT) Certified Leap Therapist Practice Test
← All CLT Flashcard Decks

LEAP Protocol & MRT Interpretation Flashcards

7 cards from real CLT practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 LEAP Protocol & MRT Interpretation flashcards as text

  1. Which chemical additive is commonly included in MRT panels and implicated in headache and IBS symptoms?

    Answer: Monosodium glutamate (MSG)

    MSG is a glutamate-based flavor enhancer frequently found reactive on MRT panels and associated with headache, GI distress, and other sensitivity-related symptoms.

  2. The MRT is performed by Oxford Biomedical Technologies (OBT). Which aspect of the test is considered a key advantage over standard IgG food sensitivity tests?

    Answer: It measures functional white blood cell response regardless of the immune pathway involved

    MRT captures the net effect of all immune pathways (IgG, IgM, complement, non-immunologic) by measuring WBC volume change, making it broader than antibody-only tests.

  3. A CLT working with a patient who has ADHD-like symptoms and food sensitivities should be especially aware that LEAP outcomes in children often depend heavily on:

    Answer: Family and caregiver compliance with the dietary protocol

    In pediatric LEAP cases, symptom improvement is strongly tied to caregiver adherence, since children cannot independently manage their own diet.

  4. Which statement about the relationship between LEAP and IgE-mediated food allergies is most accurate?

    Answer: LEAP addresses non-IgE-mediated food sensitivities, which are distinct from true IgE allergies

    LEAP targets delayed, non-IgE food sensitivities; true IgE-mediated allergies (anaphylaxis risk) require separate allergy management and must never be replaced by the LEAP protocol.

  5. Research on LEAP therapy in IBS patients has generally reported symptom improvement rates of approximately:

    Answer: 70–90%

    Clinical studies and practitioner outcome data consistently show symptom improvement rates of approximately 70–90% in IBS patients following the LEAP ImmunoCalm protocol.

  6. A CLT should document and monitor which patient lab value to confirm that systemic inflammation is decreasing alongside dietary changes during LEAP therapy?

    Answer: C-reactive protein (CRP)

    C-reactive protein is a widely used marker of systemic inflammation; tracking it provides objective evidence of reduced inflammatory activity during LEAP dietary intervention.

  7. Under the LEAP protocol, if a patient reports no improvement after 3 weeks on their ImmunoCalm diet, the CLT's first action should be to:

    Answer: Assess adherence, hidden food exposures, and label-reading accuracy

    Non-response most commonly results from hidden reactive food exposures through cross-contamination, undisclosed ingredients, or labeling errors rather than failure of the MRT itself.